RUBICON

Rubicon Research Share Price

 

 

Start SIP in RUBICON

Start SIP

Performance

  • Low
  • ₹662
  • High
  • ₹732
  • 52 Week Low
  • ₹571
  • 52 Week High
  • ₹732
  • Open Price₹676
  • Previous Close₹654
  • Volume5,056,058

Investment Returns

  • Over 1 Month + 47.18%
  • Over 3 Month + 47.18%
  • Over 6 Month + 47.18%
  • Over 1 Year + 47.18%

Smart Investing Starts Here Start SIP with Rubicon Research for Steady Growth!

Invest Now

Rubicon Research Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -
  • PEG Ratio
  • -
  • Market Cap Cr
  • 11,760
  • P/B Ratio
  • 19.8
  • Average True Range
  • 29.61
  • EPS
  • 8.16
  • Dividend Yield
  • 0
  • MACD Signal
  • -
  • RSI
  • 67.95
  • MFI
  • 88.14

Rubicon Research Financials

Rubicon Research Technicals

EMA & SMA

Current Price
₹713.80
+ 59.45 (9.09%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 7
  • 20 Day
  • ₹624.30
  • 50 Day
  • -
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

702.63 Pivot Speed
  • R3 812.77
  • R2 772.33
  • R1 743.07
  • S1 673.37
  • S2 632.93
  • S3 603.67

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

N/A

Group Rank

Rubicon Research develops, manufactures, and markets branded specialty and generic prescription drugs across the U.S. and other regulated markets. With two U.S. FDA-approved plants in Maharashtra and R&D centers in India and Canada, it offers diverse oral, nasal, and ophthalmic formulations.

Rubicon Research Ltd has an operating revenue of Rs. 2,155.07 Cr. on a trailing 12-month basis. An annual revenue growth of 49% is outstanding, Pre-tax margin of 15% is great, ROE of 24% is exceptional. The company has a reasonable debt to equity of 12%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 5% and 5% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 4 which is a POOR score indicating inconsistency in earnings, a RS Rating of 66 which is FAIR indicating the recent price performance, Group Rank of 76 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Rubicon Research Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-13 Quarterly Results

Rubicon Research F&O

Rubicon Research Shareholding Pattern

59.99%
5.63%
0.44%
5.37%
1.86%
18.28%
8.43%

About Rubicon Research

  • NSE Symbol
  • RUBICON
  • BSE Symbol
  • 544578
  • Managing Director
  • Ms. Pratibha Pilgaonkar
  • ISIN
  • INE506V01022

Similar Stocks to Rubicon Research

Rubicon Research FAQs

Rubicon Research share price is ₹713 As on 15 November, 2025 | 08:35

The Market Cap of Rubicon Research is ₹11759.9 Cr As on 15 November, 2025 | 08:35

The P/E ratio of Rubicon Research is As on 15 November, 2025 | 08:35

The PB ratio of Rubicon Research is 19.8 As on 15 November, 2025 | 08:35

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23